{"pmid":32492407,"pmcid":"PMC7250787","title":"Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.","text":["Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.","The SARS-CoV-2 pandemic that causes COVID-19 respiratory syndrome has caused global public health and economic crises, necessitating rapid development of vaccines and therapeutic countermeasures. The world-wide response to the COVID-19 pandemic has been unprecedented with government, academic, and private partnerships working together to rapidly develop vaccine and antibody countermeasures. Many of the technologies being used are derived from prior government-academic partnerships for response to other emerging infections.","Cell","Sempowski, Gregory D","Saunders, Kevin O","Acharya, Priyamvada","Wiehe, Kevin J","Haynes, Barton F","32492407"],"abstract":["The SARS-CoV-2 pandemic that causes COVID-19 respiratory syndrome has caused global public health and economic crises, necessitating rapid development of vaccines and therapeutic countermeasures. The world-wide response to the COVID-19 pandemic has been unprecedented with government, academic, and private partnerships working together to rapidly develop vaccine and antibody countermeasures. Many of the technologies being used are derived from prior government-academic partnerships for response to other emerging infections."],"journal":"Cell","authors":["Sempowski, Gregory D","Saunders, Kevin O","Acharya, Priyamvada","Wiehe, Kevin J","Haynes, Barton F"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492407","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.cell.2020.05.041","keywords":["blacksquare, square, filledblacksquare, square, filledblacksquare, square, filled"],"topics":["Treatment"],"weight":1,"_version_":1668892169356705793,"score":9.490897,"similar":[{"pmid":32460358,"title":"The early landscape of COVID-19 vaccine development in the UK and rest of the world.","text":["The early landscape of COVID-19 vaccine development in the UK and rest of the world.","Since the first WHO notification on 31st December 2019, COVID-19, the respiratory disease caused by the coronavirus SARS-CoV-2, has been responsible for over 4 million confirmed infections, and almost 300,000 deaths worldwide. The pandemic has led to over half of the world's population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to prevent further waves of infections as lockdown measures are lifted. As one of the most effective countermeasures against infectious diseases, an efficacious vaccine is considered crucial to containing the COVID-19 pandemic. Following the publication of the genome sequence of SARS-CoV-2, vaccine development has accelerated at an unprecedented pace across the world. Here we review the different platforms employed to develop vaccines, the standard timelines of development and how they can be condensed in a pandemic situation. We focus on vaccine development in the UK and vaccines which have entered clinical trials around the world.","Immunology","Sharpe, Hannah R","Gilbride, Ciaran","Allen, Elizabeth","Belij-Rammerstorfer, Sandra","Bissett, Cameron","Ewer, Katie","Lambe, Teresa","32460358"],"abstract":["Since the first WHO notification on 31st December 2019, COVID-19, the respiratory disease caused by the coronavirus SARS-CoV-2, has been responsible for over 4 million confirmed infections, and almost 300,000 deaths worldwide. The pandemic has led to over half of the world's population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to prevent further waves of infections as lockdown measures are lifted. As one of the most effective countermeasures against infectious diseases, an efficacious vaccine is considered crucial to containing the COVID-19 pandemic. Following the publication of the genome sequence of SARS-CoV-2, vaccine development has accelerated at an unprecedented pace across the world. Here we review the different platforms employed to develop vaccines, the standard timelines of development and how they can be condensed in a pandemic situation. We focus on vaccine development in the UK and vaccines which have entered clinical trials around the world."],"journal":"Immunology","authors":["Sharpe, Hannah R","Gilbride, Ciaran","Allen, Elizabeth","Belij-Rammerstorfer, Sandra","Bissett, Cameron","Ewer, Katie","Lambe, Teresa"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460358","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/imm.13222","keywords":["covid-19","sars-cov-2","vaccine"],"locations":["GBR","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Treatment"],"weight":1,"_version_":1667967698967986176,"score":121.7345},{"pmid":32390971,"pmcid":"PMC7193113","title":"The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.","text":["The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.","Emerging coronaviruses (CoV) are constant global public health threats to society. Multiple ongoing clinical trials for vaccines and antivirals against CoVs showcase the availability of medical interventions to both prevent and treat the future emergence of highly pathogenic CoVs in human. However, given the diverse nature of CoVs and our close interactions with wild, domestic and companion animals, the next epidemic zoonotic CoV could resist the existing vaccines and antivirals developed, which are primarily focused on Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS CoV). In late 2019, the novel CoV (SARS-CoV-2) emerged in Wuhan, China, causing global public health concern. In this review, we will summarize the key advancements of current vaccines and antivirals against SARS-CoV and MERS-CoV as well as discuss the challenge and opportunity in the current SARS-CoV-2 crisis. At the end, we advocate the development of a \"plug-and-play\" platform technologies that could allow quick manufacturing and administration of broad-spectrum countermeasures in an outbreak setting. We will discuss the potential of AAV-based gene therapy technology for in vivo therapeutic antibody delivery to combat SARS-CoV-2 outbreak and the future emergence of severe CoVs.","Front Microbiol","Tse, Longping V","Meganck, Rita M","Graham, Rachel L","Baric, Ralph S","32390971"],"abstract":["Emerging coronaviruses (CoV) are constant global public health threats to society. Multiple ongoing clinical trials for vaccines and antivirals against CoVs showcase the availability of medical interventions to both prevent and treat the future emergence of highly pathogenic CoVs in human. However, given the diverse nature of CoVs and our close interactions with wild, domestic and companion animals, the next epidemic zoonotic CoV could resist the existing vaccines and antivirals developed, which are primarily focused on Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS CoV). In late 2019, the novel CoV (SARS-CoV-2) emerged in Wuhan, China, causing global public health concern. In this review, we will summarize the key advancements of current vaccines and antivirals against SARS-CoV and MERS-CoV as well as discuss the challenge and opportunity in the current SARS-CoV-2 crisis. At the end, we advocate the development of a \"plug-and-play\" platform technologies that could allow quick manufacturing and administration of broad-spectrum countermeasures in an outbreak setting. We will discuss the potential of AAV-based gene therapy technology for in vivo therapeutic antibody delivery to combat SARS-CoV-2 outbreak and the future emergence of severe CoVs."],"journal":"Front Microbiol","authors":["Tse, Longping V","Meganck, Rita M","Graham, Rachel L","Baric, Ralph S"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32390971","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3389/fmicb.2020.00658","keywords":["2019 ncov","mers- and sars-cov","adeno-associate virus","antivirals","coronavirus (cov)","passive immunization strategy","vaccine"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666528580072374274,"score":108.80183},{"pmid":32344202,"title":"Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.","text":["Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.","The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.","EBioMedicine","de Alwis, Ruklanthi","Chen, Shiwei","Gan, Esther S","Ooi, Eng Eong","32344202"],"abstract":["The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis."],"journal":"EBioMedicine","authors":["de Alwis, Ruklanthi","Chen, Shiwei","Gan, Esther S","Ooi, Eng Eong"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344202","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.ebiom.2020.102768","keywords":["covid-19","coronavirus","polyclonal hyperimmune globulin","sars-cov-2","vaccines"],"topics":["Treatment"],"weight":1,"_version_":1666138495772524545,"score":103.797745},{"pmid":32393526,"title":"A strategic approach to COVID-19 vaccine R&D.","text":["A strategic approach to COVID-19 vaccine R&D.","A public-private partnership and platform for harmonized clinical trials aims to accelerate licensure and distribution.","Science","Corey, By Lawrence","Mascola, John R","Fauci, Anthony S","Collins, Francis S","32393526"],"abstract":["A public-private partnership and platform for harmonized clinical trials aims to accelerate licensure and distribution."],"journal":"Science","authors":["Corey, By Lawrence","Mascola, John R","Fauci, Anthony S","Collins, Francis S"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393526","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1126/science.abc5312","topics":["Treatment"],"weight":1,"_version_":1666627827910311936,"score":100.82452},{"pmid":32075877,"pmcid":"PMC7164637","title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.","text":["Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.","The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.","Science","Wrapp, Daniel","Wang, Nianshuang","Corbett, Kizzmekia S","Goldsmith, Jory A","Hsieh, Ching-Lin","Abiona, Olubukola","Graham, Barney S","McLellan, Jason S","32075877"],"abstract":["The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis."],"journal":"Science","authors":["Wrapp, Daniel","Wang, Nianshuang","Corbett, Kizzmekia S","Goldsmith, Jory A","Hsieh, Ching-Lin","Abiona, Olubukola","Graham, Barney S","McLellan, Jason S"],"date":"2020-02-21T11:00:00Z","year":2020,"_id":"32075877","source":"PubMed","week":"20208|Feb 17 - Feb 23","doi":"10.1126/science.abb2507","e_drugs":["Sulfur"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490831634432,"score":97.55763}]}